Identification
- Summary
-
Sulthiameis a carbonic anhydrase inhibitor used primarily in benign focal epilepsies of childhood that may be useful as an adjunct therapy in a variety of other refractory epilepsies.
- Generic Name
- Sulthiame
- DrugBank Accession Number
- DB08329
- Background
-
Not Available
- Type
- Small Molecule
- Groups
- Approved
- Structure
-
Structure for Sulthiame (DB08329)
- Weight
-
Average: 290.359
Monoisotopic: 290.039498326 - Chemical Formula
- C10H14N2O4S2
- Synonyms
-
- Sulthiame
- Sultiame
- Sultiamo
- Sultiamum
- 走读生al IDs
-
- Bayer A-168
- R-594
- RIKER 594
- RIKER-594
- RP 10284
- RP-10284
Pharmacology
- Indication
-
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning models
with evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets. - Associated Conditions
- Contraindications & Blackbox Warnings
-
Avoid life-threatening adverse drug eventsImprove clinical decision support with information oncontraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support. - Pharmacodynamics
-
Not Available
- Mechanism of action
-
Target Actions Organism UCarbonic anhydrase 2 Not Available Humans - Absorption
-
Not Available
- Volume of distribution
-
Not Available
- Protein binding
-
Not Available
- Metabolism
- Not Available
- Route of elimination
-
Not Available
- Half-life
-
Not Available
- Clearance
-
Not Available
- Adverse Effects
-
Improve decision support & research outcomesWith structured adverse effects data, including:blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Improve decision support & research outcomes with our structured adverse effects data. - Toxicity
-
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRsBrowse all" title="" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
- Not Available
Interactions
- 药物的相互作用Learn More" title="" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
-
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your software1,2-Benzodiazepine The risk or severity of adverse effects can be increased when Sulthiame is combined with 1,2-Benzodiazepine. Acetazolamide The risk or severity of adverse effects can be increased when Acetazolamide is combined with Sulthiame. Acetophenazine The risk or severity of adverse effects can be increased when Acetophenazine is combined with Sulthiame. Agomelatine The risk or severity of adverse effects can be increased when Agomelatine is combined with Sulthiame. Alfentanil The risk or severity of adverse effects can be increased when Alfentanil is combined with Sulthiame. Alimemazine The risk or severity of adverse effects can be increased when Alimemazine is combined with Sulthiame. Almotriptan The risk or severity of adverse effects can be increased when Almotriptan is combined with Sulthiame. Alosetron The risk or severity of adverse effects can be increased when Alosetron is combined with Sulthiame. Alprazolam The risk or severity of adverse effects can be increased when Alprazolam is combined with Sulthiame. Alverine The risk or severity of adverse effects can be increased when Alverine is combined with Sulthiame. 
Identify potential medication risksEasily compare up to 40 drugs with our drug interaction checker.Get severity rating, description, and management advice.Learn more - Food Interactions
-
- Take with food. Taking sulthiame with food, may reduce gastrointestinal upset.
Products
-
Drug product information from 10+ global regionsOur datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions. - International/Other Brands
- Conadil/Contravul/Elisal/Ospolot
Categories
- ATC Codes
- N03AX03 — Sultiame
- Drug Categories
- Chemical TaxonomyProvided byClassyfire
-
- Description
- This compound belongs to the class of organic compounds known as sulfanilides. These are organic aromatic compounds containing a sulfanilide moiety, with the general structure RS(=O)(=O)NC1=CC=CC=C1.
- Kingdom
- Organic compounds
- Super Class
- Benzenoids
- Class
- Benzene and substituted derivatives
- Sub Class
- Sulfanilides
- Direct Parent
- Sulfanilides
- Alternative Parents
- Benzenesulfonamides/Benzenesulfonyl compounds/Delta sultams/Organosulfonamides/Organic sulfonamides/Aminosulfonyl compounds/Azacyclic compounds/Organopnictogen compounds/Organonitrogen compounds/Organic oxides show 1 more
- Substituents
- 1,2-thiazinane/Aminosulfonyl compound/Aromatic heteromonocyclic compound/Azacycle/Benzenesulfonamide/Benzenesulfonyl group/Delta-sultam/Hydrocarbon derivative/Organic nitrogen compound/Organic oxide show 11 more
- Molecular Framework
- Aromatic heteromonocyclic compounds
- 走读生al Descriptors
- Not Available
- Affected organisms
-
- Humans and other mammals
Chemical Identifiers
- UNII
- I00Q766CZ2
- CAS number
- 61-56-3
- InChI Key
- HMHVCUVYZFYAJI-UHFFFAOYSA-N
- InChI
-
InChI=1S/C10H14N2O4S2/c11-18(15,16)10-5-3-9(4-6-10)12-7-1-2-8-17(12,13)14/h3-6H,1-2,7-8H2,(H2,11,15,16)
- IUPAC Name
-
(4) - 1 1-dioxo-1lambda6 2-thiazinan-2-yl benzene-1-sulfonamide
- SMILES
-
NS(=O)(=O)C1=CC=C(C=C1)N1CCCCS1(=O)=O
References
- 一般引用
- Not Available
- 走读生al Links
-
- PubChem Compound
- 5356
- PubChem Substance
- 99444800
- ChemSpider
- 5163
- BindingDB
- 26999
- 10240
- ChEBI
- 32171
- ChEMBL
- CHEMBL328560
- ZINC
- ZINC000000002119
- PDBe Ligand
- OSP
- Wikipedia
- Sultiame
- PDB Entries
- 2q1q
Clinical Trials
- Clinical TrialsLearn More" title="" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
-
Phase Status Purpose Conditions Count 3 Terminated Treatment Rolandic Epilepsy 1 2 Recruiting Treatment Obstructive Sleep Apnea (OSA) 1 1 Completed Other Epilepsies 1 Not Available Unknown Status Not Available Epilepsies 1
Pharmacoeconomics
- Manufacturers
-
Not Available
- Packagers
-
Not Available
- Dosage Forms
-
Form Route Strength Tablet, film coated Oral - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
-
Property Value Source Water Solubility 1.96 mg/mL ALOGPS logP 0.37 ALOGPS logP -0.27 Chemaxon logS -2.2 ALOGPS pKa (Strongest Acidic) 10.55 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 4 Chemaxon Hydrogen Donor Count 1 Chemaxon Polar Surface Area 97.54 Å2 Chemaxon Rotatable Bond Count 2 Chemaxon Refractivity 67.46 m3·mol-1 Chemaxon Polarizability 27.86 Å3 Chemaxon Number of Rings 2 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule No Chemaxon MDDR-like规则 No Chemaxon - Predicted ADMET Features
-
Property Value Probability Human Intestinal Absorption + 0.9633 Blood Brain Barrier + 0.9382 Caco-2 permeable - 0.6039 P-glycoprotein substrate Non-substrate 0.6429 P-glycoprotein inhibitor I Non-inhibitor 0.7975 P-glycoprotein inhibitor II Non-inhibitor 0.9393 Renal organic cation transporter Non-inhibitor 0.7331 CYP450 2C9 substrate Non-substrate 0.7677 CYP450 2D6 substrate Non-substrate 0.8014 CYP450 3A4 substrate Non-substrate 0.5196 CYP450 1A2 substrate Non-inhibitor 0.8171 CYP450 2C9 inhibitor Non-inhibitor 0.5435 CYP450 2D6 inhibitor Non-inhibitor 0.9277 CYP450 2C19 inhibitor Inhibitor 0.6191 CYP450 3A4 inhibitor Non-inhibitor 0.6993 CYP450 inhibitory promiscuity High CYP Inhibitory Promiscuity 0.5444 Ames test Non AMES toxic 0.6894 Carcinogenicity Non-carcinogens 0.8414 Biodegradation Not ready biodegradable 0.9972 Rat acute toxicity 1.7952 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.8038 hERG inhibition (predictor II) Non-inhibitor 0.6671
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
-
Spectrum Spectrum Type Splash Key Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available
Targets
Build, predict & validate machine-learning models
Use our structured and evidence-based datasets tounlock new
insights and accelerate drug research.
insights and accelerate drug research.
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
-
Unknown
- General Function
- Zinc ion binding
- Specific Function
- Essential for bone resorption and osteoclast differentiation (By similarity). Reversible hydration of carbon dioxide. Can hydrate cyanamide to urea. Involved in the regulation of fluid secretion in...
- Gene Name
- CA2
- Uniprot ID
- P00918
- Uniprot Name
- Carbonic anhydrase 2
- 分子量
- 29245.895 Da
References
- Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [Article]
Drug created at September 15, 2010 21:30 / Updated at June 19, 2021 00:27